HHLR Advisors’s Sarepta Therapeutics SRPT Stock Holding History

HHLR Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,404	Closed	-$1.43M	–	72
2023 Q1	$1.43M	Buy	+10,404	New	+$1.35M	0.03%	64

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors's SRPT Position: Q2 2023 in Review

HHLR Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 10,404 shares — an estimated $1.43M sold.

HHLR Advisors first reported a position in SRPT in Q1 2023 and held it in 1 quarter. The position peaked at $1.43M in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

HHLR Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
HHLR Advisors sold 10,404 Sarepta Therapeutics shares in Q2 2023, an estimated $1.43M.
HHLR Advisors first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 1 quarter.
HHLR Advisors's Sarepta Therapeutics position peaked at $1.43M in Q1 2023.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on HHLR Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.